EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 5, 2013, Pages 620-627

  Li, Huzi ^a   Guo, Zhi ^a   Si, Tongguo ^a   Wang, Haitao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

cryoablation; hepatocellular carcinoma; prognosis; response evaluation criteria

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CRYOABLATION; EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MODIFIED RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL PREDICTION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CRYOSURGERY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84876411107     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835ced13     Document Type: Article

References (22)

1. Gage AA. History of cryosurgery. Semin Surg Oncol 1998; 14:99-109. (Pubitemid 128756770)
2. Zhou L, Yang YP, Feng YY, Lu YY, Wang CP, Wang XZ, et al. Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study. Ai Zheng 2009; 28:45-48.
3. Zhou L, Fu JL, Lu YY, Fu BY, Wang CP, An LJ, et al. Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol 2010; 45:968-978.
4. Seifert JK, Junginger T. Cryotherapy for liver tumors: current status, perspectives, clinical results, and review of literature. Technol Cancer Res Treat 2004; 3:151-163. (Pubitemid 38544262)
5. Chen HW, Lai EC, Zhen ZJ, Cui WZ, Liao S, Lau WY. Ultrasound-guided percutaneous cryotherapy of hepatocellular carcinoma. Int J Surg 2011; 9:188-191.
6. Yang Y, Lu Y,Wang C, Bai W, Qu J, Chen Y, et al. Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys 2012; 63:159-169.
7. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006; 24:3245-3251. (Pubitemid 46622065)
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
9. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol 2001; 35:421-430. (Pubitemid 32844200)
10. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60.
11. Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40:1352-1360. (Pubitemid 39657009)
12. Gravante G, Sconocchia G, Ong SL, Dennison AR, Lloyd DM. Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies. Liver Int 2009; 29:18-24.
13. Zhou L, Wang C, Lu YY, Bai WL, Qu JH, Lou M. Decrease in size of nontreated lesions after cryoablation for hepatocellular carcinoma. Hepatogastroenterology 2012; 59:252-254.
14. Bruix J, Sherman M. American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-1022.
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz L H, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
16. Hunter RD. WHO handbook for reporting results of cancer treatment. Int J Radiat Biol 1980; 38:481-481.
17. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, De Lope CR, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009; 115:616-623.
18. Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118:147-156.
19. Keppke AL, Salem R, Reddy D, Huang J, Jin J, Larson AC, et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. Am J Roentgenol 2007; 188:768-775.
20. Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010. pp. 1062-1069.
21. Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, et al.Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012; 262:708-718.
22. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55:1309-1316.